Macrophages as effector cells in interleukin 12-induced T cell-dependent tumor rejection

Cancer Research

Volumn 62, Issue 17, 2002, Pages 5069-5075

  Tsung, Kangla ^a   Dolan, James P ^a   Tsung, Ying L ^a   Norton, Jeffrey A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; FAS ANTIBODY; FAS LIGAND; INTERLEUKIN 12; NITRIC OXIDE; PARAFORMALDEHYDE; THIOGLYCOLIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; ASCITES TUMOR; CANCER MODEL; CELL INFILTRATION; EFFECTOR CELL; MACROPHAGE; MACROPHAGE ACTIVATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN; T LYMPHOCYTE; TUMOR CELL DESTRUCTION; TUMOR IMMUNITY; TUMOR REJECTION;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL COMMUNICATION; CYCLOPHOSPHAMIDE; CYTOTOXICITY, IMMUNOLOGIC; FAS LIGAND PROTEIN; FEMALE; INTERLEUKIN-12; MACROPHAGE ACTIVATION; MACROPHAGES; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; PORE FORMING CYTOTOXIC PROTEINS; SARCOMA, EXPERIMENTAL; T-LYMPHOCYTES;

EID: 0036735299     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Liver NK1.1 + CD4+ αβ T cells activated by IL-12 as a major effector in inhibition of experimental tumor metastasis
2. Cloning of cDNA for natural killer cell stimulatory factor, a heterodimeric cytokine with multiple biologic effects on T and natural killer cells
3. IL-12 augments antigen-dependent proliferation of activated T lymphocytes
4. IL-12 acts selectively on CD8α-dendritic cells to enhance presentation of a tumor peptide in vivo
5. Requirement for Vα14 NKT Cells in IL-12-mediated rejection of tumors
6. Recombinant IL-12 administration induces tumor regression in association with IFN-γ production
7. Tumor-bearing mice exhibit a progressive increase in tumor antigen-presenting cell function and a reciprocal decrease in tumor antigen-responsive CD4+ T cell activity
8. Influence of interleukin 12 on p53 peptide vaccination against established Meth A sarcoma
9. IL-12 induces T helper 1-directed antitumor response
10. Immune response against large tumors eradicated by treatment with cyclophosphamide and interleukin-12
11. Pre-existing tumor-sensitized T cells are essential for eradication of established tumors by IL-12 and cyclophosphamide plus IL-12
12. Natural killcr-like nonspecific tumor cell lysis mediated by specific ligand-activated Vα14 NKT cells
13. Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity
14. Cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways
15. Decreased tumor surveillance in perforin-deficient mice
16. Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B 16 melanoma vaccine. Comparison of prophylaxis and therapy
17. Perforin-dependent NK cell cytotoxicity is sufficient for anti-metastatic effect of IL-12
18. Unique murine tumor-associated antigens identified by tumor infiltrating lymphocytes
19. Cell-associated tumor necrosis factor (TNF) as a killing mechanism of activated cytotoxic macrophages
20. Membrane-associated interleukin 1α as a mediator of tumor cell killing by human blood monocytes fixed with paraformaldehyde
21. Perforin/Fas-ligand double deficiency is associated with macrophage expansion and severe pancreatitis
22. Energy metabolism and T-cell-mediated cytolysis. I. Synergism between inhibitors of respiration and glycolysis
23. A comparison of the effects of metabolic inhibitors upon direct and antibody-dependent lymphocyte mediated cytotoxicity
24. Natural killer cell activation-associated induction of target cell DNA fragmentation in a spontaneously regressing rat histiocytoma
25. Macrophage accumulation in murine ascites tumors. I. Cytoxan-induced dominance of macrophages over tumor cells and the anti-tumor effect of endotoxin
26. Regulation of murine macrophage IL-12 production. Activation of macrophages in vivo, restimulation in vitro, and modulation by other cytokines
27. Molecular mechanisms underlying IFN-γ-mediated tumor growth inhibition induced during tumor immunotherapy with rIL-12
28. The role of IFN-γ in rejection of established tumors by IL-12: Source of production and target
29. Effects of cyclophosphamide on macrophage numbers, functions and progenitor cells
30. Macrophages as accessory cells for class 1 MHC-restricted immune responses
31. Liposome mediated depletion of macrophages: Mechanism of action, preparation of liposomes and applications
32. Cooperation of immune lymphoid cells with macrophages in tumour immunity
33. Augmentation of the adoptive transfer of specific tumor immunity by non-specifically immunized macrophages
34. T-cell-mediated concomitant immunity to syngeneic tumors. I. Activated macrophages as the expressors of nonspecific immunity to unrelated tumors and bacterial parasites
35. Thy and Ly markers on lymphocytes initiating tumor rejection
36. Macrophages and antitumor reactions
37. The mechanism of tumor growth inhibition by tumor-specific Lyt-1+2-T cells. I. Antitumor effect of Lyt-1+2-T cells depends on the existence of adherent cells
38. Evidence for the involvement of cytolytic macrophages in rejection of SV40-induced tumors
39. Eradication of a disseminated syngeneic mouse lymphoma by systemic adoptive transfer of immune lymphocytes and its dependence upon a host component(s)
40. Cellular requirements for tumor-specific immunity elicited by heat shock proteins: Tumor rejection antigen gp96 primes CD8+ T cells in vivo
41. IFN-γ- and cell-to-cell contact-dependent cytotoxicity of allograft-induced macrophages against syngeneic tumor cells and cell lines: An application of allografting to cancer treatment
42. Activated murine macrophages induce apoptosis in tumor cells through nitric oxide-dependent or -independent mechanisms